Skip to main content
Premium Trial:

Request an Annual Quote

Single-Cell Tech Firm Parse Biosciences Raises $50M

NEW YORK – Seattle-based Parse Biosciences said Thursday that it has raised $50 million between a Series C financing round and a debt facility from Horizon Technology Finance.

Soleus Capital led the round, joined by Bioeconomy Capital, Janus Henderson Investors, Marshall Wace, Sahsen Ventures, and Saras Capital.

The firm did not disclose how much of the $50 million came from the financing round and how much was associated with the debt facility.

In a statement, Parse said it would use the funding to expand and scale to meet "increasing" demand for its single-cell technology.

"Parse's unique technology is enabling investigators to conduct groundbreaking research and expand the overall genomics market," Soleus Capital Partner David Canner said in a statement. "We are proud to partner with Parse and its management team as the company grows into a preeminent player in the genomics space."

Parse, a University of Washington spinout, said it has now raised over $100 million. It closed a $41.5 million Series B financing round in February 2022.